Literature DB >> 3467153

Mitogenic effect of bradykinin and of des-Arg9-bradykinin on cultured fibroblasts.

F Marceau, B Tremblay.   

Abstract

Bradykinin (BK) and its fragment des-Arg9-BK failed to stimulate thymidine incorporation in all but one observed fibroblast cultures derived from human amniotic fluid or rabbit dermis. The rabbit dermis fibroblast line designated R51 acquired the capacity to increase its DNA synthesis in response to kinins after several weeks in culture. It was more sensitive to des-Arg9-BK than to BK and the effect of both peptides was antagonized by the analog Leu8, des-Arg9-BK; these features are shared with certain smooth muscle preparations responsive to kinins such as the rabbit aorta. Recently isolated rabbit dermis or human amniotic fibroblasts could not be made responsive to kinins by pre-incubating them with bacterial lipopolysaccharide. The line R51 released more PGE2 than baseline when stimulated with BK or des-Arg9-BK at low concentrations; it was also doubling faster than recently isolated cells of similar origin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3467153     DOI: 10.1016/0024-3205(86)90666-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  Pulse exposure to protein synthesis inhibitors enhances vascular responses to des-Arg9-bradykinin: possible role of interleukin-1.

Authors:  D deBlois; J Bouthillier; F Marceau
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

2.  Soluble CD13 induces inflammatory arthritis by activating the bradykinin receptor B1.

Authors:  Pei-Suen Tsou; Chenyang Lu; Mikel Gurrea-Rubio; Sei Muraoka; Phillip L Campbell; Qi Wu; Ellen N Model; Matthew E Lind; Sirapa Vichaikul; Megan N Mattichak; William D Brodie; Jonatan L Hervoso; Sarah Ory; Camila I Amarista; Rida Pervez; Lucas Junginger; Mustafa Ali; Gal Hodish; Morgan M O'Mara; Jeffrey H Ruth; Aaron M Robida; Andrew J Alt; Chengxin Zhang; Andrew G Urquhart; Jeffrey N Lawton; Kevin C Chung; Tristan Maerz; Thomas L Saunders; Vincent E Groppi; David A Fox; M Asif Amin
Journal:  J Clin Invest       Date:  2022-06-01       Impact factor: 19.456

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.